Impact of COVID-19 on pre-existing liver disease




Juan M. Abdo-Francis, Servicio de Gastroenterología, Hospital Ángeles Acoxpa, Ciudad de México, México
Rosalba Moreno-Alcantar, Servicio de Gastroenterología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México, México
José L. Pérez-Hernández, Servicio de Gastroenterología, Hospital General de México, Ciudad de México, México
José M. Remes-Troche, Instituto de Investigaciones Biológicas, Veracruz, México
Antonio Velarde-Ruiz Velasco, Servicio de Gastroenterología, Hospital Civil, Guadalajara, Jalisco, México
Eira Cerda-Reyes, Servicio de Gastroenterología, Hospital Civil, Guadalajara, Jalisco; 6Clínica de Hígado, Hospital Central Militar, Ciudad de México, México
Fátima Higuera-de la Tijera, Servicio de Gastroenterología, Hospital General de México, Ciudad de México, México
Graciela Castro-Narro, Servicio de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México. México


Patients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the relationship between COVID 19 and preexistence of liver disease. The proportion of COVID-19 patients with abnormal liver function on admission ranged from 40 % to 75 % and the proportion with liver injury was close to 30%. Current studies show an important association between preexisting liver disease and COVID-19. The presence of cirrhosis is now an independent predictor of severity for COVID-19 and prolonged hospitalization in this group of patients. Patients with cirrhosis have a higher mortality rate, and this rate rises with increasing severity.



Keywords: Pre-existing liver disease. COVID-19. COVID and cirrhosis.